1,1-Cyclobutanedicarboxylatodiammineplatinum (II) Cas:41575-94-4
| Catalog Number | XD90684 |
| Product Name | 1,1-Cyclobutanedicarboxylatodiammineplatinum (II) |
|
CAS |
41575-94-4 |
|
Molecular Formula |
C6H12N2O4Pt |
|
Molecular Weight |
371.25 |
| Storage Details | 2-8°C |
| Harmonized Tariff Code | 28439090 |
Product Specification
| Appearance | White to off-white powder |
| Assay | 99% |
| Water | ≤0.5% |
| Loss on Drying | ≤0.5% |
| Chlorides | ≤100ppm |
| Related Substances | ≤0.25% |
| Any Unspecified Impurity | ≤ 0.1% |
| All other impurities | ≤0.5% |
| 1,1-Cyclobutanedicarboxylic acid | ≤ 0.5% |
Second-generation platinum complex antineoplastic drugs. The antitumor spectrum and antitumor activity are similar to those of cisplatin, but the water solubility is better than that of cisplatin, and the toxicity to the kidney is also lower. It has good curative effect on small cell lung cancer, ovarian cancer, head and neck squamous cell carcinoma, testicular tumor, malignant lymphoma, etc. It can also be used for cervical cancer, bladder cancer, etc.
The second-generation platinum anticancer drugs have basically the same functions and uses as cisplatin. It is more active than cisplatin for some tumors, and is stronger than cisplatin as a radiosensitizer under hypoxic conditions. Mainly used for ovarian cancer, testicular cancer, small cell lung cancer and head and neck cancer.
Carboplatin is a platinum-based anticancer drug that damages DNA by forming intrachain conjugation to adjacent guanine residues. The antitumor effect of these drugs is achieved by loss of DNA mismatch repair (MMR vaccine) activity and induction of programmed cell death
